Citations

Clear

4 citation(s) found for "Ge, Ying Ping".

A Proteoform-Resolved Atlas of Human Cardiac Histones
Gao, Zhan, Clemmer, Isabella R., Chan, Hsin-Ju, Osei, Kwame, Weir, Thomas S., Fischer, Matthew S. , Gearhart, Robert, Price, Scott J., Zhu, Y., Wu, Jingshing, Zhu, Wuqiang , Zhu, Wuqiang , Gao, Zhan , Chan, Hsin‐Ju , Osei, Kwame, Rogers, Holden T. , Gearhart, Robert L., Price, Scott J., Brasier, Allan R. , Ge, Ying Ping

Mayo Clinic

No container title available | February 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8811072/v1 | PMID 41727594 Get It

Abstract Histones variant composition and post-translational modifications (PTMs) of core and linker histones jointly orchestrate chromatin architecture and tissue-specific gene regulation. However, capturing the full complexity of the “histone code” in native human tissues remains challenging. Here we present a human cardiac histone proteoform atlas—comprising intact histone variants with combinatorial PTMs—enabled by a streamlined top‑down proteomics workflow. In a single one‑dimensional reversed‑phase liquid chromatography (LC)-mass spectrometry (MS) run, we achieve baseline separation of all four core histone families (H2A, H2B, H3, and H4) together with the linker histone H1 directly from human myocardium. Notably, this intact-protein analysis preserves the connectivity of co-occurring PTMs to individual histone molecules to reveal the combinatorial histone code, enabling proteoform‑level quantification of histone‑variant composition and PTM stoichiometry at the chromatographic scale. Targeted MS/MS directly resolves co-occurring PTM combinations and distinguishes highly homologous histone isoforms. Using this approach, we assemble the first comprehensive cardiac histone proteoform atlas and uncover previously unobserved histone proteoforms. More broadly, this top-down proteomics workflow provides a robust framework for proteoform-resolved analysis of histone variants and PTMs in complex biological systems.
Extracellular matrix alterations in chronic ischemic cardiomyopathy revealed by quantitative proteomics
Buck, Kevin M. , Gregorich, Zachery R. , Gao, Zhan , Price, Scott J., Rogers, Holden T. , Mann, Morgan , Aballo, Timothy J. , Chapman, Emily A. , Perciaccante, Andrew J. , Lei, Ienglam , Tang, Paul C. , Ge, Ying Ping

Mayo Clinic

JCI Insight | September 30, 2025 | Volume: 10 | Issue: 21 | Pages: No page available

10.1172/jci.insight.196933 | PMID 41026521 Get It

Ischemic cardiomyopathy (ICM) is a leading cause of heart failure characterized by extensive remodeling of the cardiac extracellular matrix (ECM). While initially adaptive, ECM deposition following ischemic injury eventually turns maladaptive, promoting adverse cardiac remodeling. The strong link between the extent of fibrosis and adverse clinical outcomes has led to growing interest in ECM-targeted therapies to prevent or reverse maladaptive cardiac remodeling in ICM; yet, the precise composition of the ECM in ICM remains poorly defined. In this study, we employed sequential protein extraction enabled by the photocleavable surfactant Azo to enrich ECM proteins from left ventricular tissues of patients with end-stage ICM and nonfailing donor hearts. High-resolution mass spectrometry–based quantitative proteomics identified and quantified over 6,000 unique protein groups, including 315 ECM proteins. We discovered significant upregulation of key ECM components, particularly glycoproteins, proteoglycans, collagens, and ECM regulators. Notably, LOXL1 , FBLN1 , and VCAN were among the most differentially expressed. Functional enrichment analyses revealed enhanced TGFB signaling, integrin-mediated adhesion, and complement activation in ICM tissues, suggesting a feedback loop driving continued ECM deposition in the end-stage failing heart. Together, our findings provide a comprehensive proteomic landscape of ECM alterations in the end-stage ICM myocardium and identify promising molecular targets for therapeutic intervention.
Extracellular Matrix Alterations in Chronic Ischemic Cardiomyopathy Revealed by Quantitative Proteomics
Buck, Kevin M. , Gregorich, Zachery R. , Aballo, Timothy J. , Gao, Zhan , Price, Scott J., Aballo, Timothy J , Rogers, Holden T. , Mann, Morgan , Chapman, Emily A. , Perciaccante, Andrew J. , Lei, Ienglam , Tang, Paul C. , Ge, Ying Ping

Mayo Clinic

No container title available | May 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.23.655833 | PMID 40501991 Get It

Abstract Ischemic cardiomyopathy (ICM) is a leading cause of heart failure characterized by extensive remodeling of the cardiac extracellular matrix (ECM). While initially adaptive, ECM deposition following ischemic injury eventually turns maladaptive, promoting adverse cardiac remodeling. The strong link between the extent of fibrosis and adverse clinical outcomes has led to growing interest in ECM targeted therapies to prevent or reverse maladaptive cardiac remodeling in ICM; yet, the precise composition of the ECM in ICM remains poorly defined. In this study, we employed a sequential protein extraction enabled by the photocleavable surfactant Azo to enrich ECM proteins from left ventricular tissues of patients with end-stage ICM (n=16) and nonfailing donor hearts (n=16). High-resolution mass spectrometry-based quantitative proteomics identified and quantified over 6,000 unique protein groups, including 315 ECM proteins. We discovered significant upregulation of key ECM components, particularly glycoproteins, proteoglycans, collagens, and ECM regulators. Notably, LOXL1, FBLN1, and VCAN were among the most differentially expressed. Functional enrichment analyses revealed enhanced TGFβ signaling, integrin-mediated adhesion, and complement activation in ICM tissues, suggesting a feedback loop driving continued ECM deposition in the end-stage failing heart. Together, our findings provide a comprehensive proteomic landscape of ECM alterations in the end-stage ICM myocardium and identify promising molecular targets for therapeutic intervention.
Can pillar suturing promote efficacy of adenotonsillectomy for pediatric osas? A prospective randomized controlled trial
Chiu, Po‐Han, Ramar, Kannan , Chen, Kuang‐Chao, Tsai, Yih‐Jeng , Lin, Chia‐Mo, Chiang, Yuh‐Chyun, Lu, Chia‐Ying, Chiang, Rayleigh Ping‐Ying , Chiu, Po-Han

Mayo Clinic

The Laryngoscope | August 5, 2013 | Volume: 123 | Issue: 10 | Pages: 2573-2577

10.1002/lary.24011 | PMID 23918531 Get It

Objectives/Hypothesis Pediatric obstructive sleep apnea syndrome ( OSAS ) is a common disorder with serious clinical implications if left untreated. The recommended initial treatment for pediatric patients with obstructive sleep apnea syndrome ( OSAS ) is adenotonsillectomy. However, recent reports have shown variable surgical results with adenotonsillectomy in the treatment of pediatric OSAS . Study Design Prospective, controlled study. Methods From April 2007 to August 2010, 24 participants were assigned alternatively to either adenotonsillectomy with pillar suturing (intervention group) or adenotonsillectomy alone (control group). Result The average improvement in apnea hypopnea index ( AHI ) was 42.6% in the control group and 79.9% in the intervention group ( P =0.037). The success rate was 50% in the control group and 91.6% in the intervention group ( P =0.034). Six patients (50%) in the intervention group achieved complete resolution of pediatric OSAS , as defined by an AHI <1/hour, compared to 2 patients (16.7%) in the control group ( P =0.097). Conclusion Adenotonsillectomy with pillar suturing showed significant improvement in treating pediatric patients with OSAS compared to adenotonsillectomy alone. The procedure is simple and safe. Level of Evidence 4. Laryngoscope , 123:2574–2578, 2013